Pioglitazone 30mg

Description

Pioglitazone 30mg PIOSTERIS 30 contains Pioglitazone 30 mg, an oral antidiabetic medication that belongs to the class of thiazolidinediones (TZDs). It is widely prescribed for the management of Type 2 Diabetes Mellitus (T2DM). By improving the body’s sensitivity to insulin, Pioglitazone helps lower blood glucose levels and provides long-term glycemic control when used alone or in combination with other antidiabetic drugs. Mechanism of Action: Pioglitazone acts as a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist. This enhances the body’s response to insulin by: Improving glucose uptake in muscle and adipose tissue. Reducing glucose production in the liver. Enhancing insulin sensitivity without increasing insulin secretion. This unique mechanism lowers blood sugar levels while minimizing the risk of hypoglycemia when used as monotherapy. Indications: PIOSTERIS 30 (Pioglitazone 30 mg) is indicated for: Management of Type 2 Diabetes Mellitus (T2DM). Patients are inadequately controlled by diet and exercise alone. Can be used as monotherapy or in combination therapy with Metformin, Sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, or Insulin. Key Benefits: Provides effective glycemic control. Enhances insulin sensitivity in peripheral tissues. Reduces fasting plasma glucose (FPG) and postprandial glucose (PPG). Helps improve HbA1c levels. May offer cardiovascular benefits in some patients by improving lipid profile. Low risk of hypoglycemia when used alone. Dosage and Administration: Usual dose: Pioglitazone 15–30 mg once daily, may be increased to 45 mg daily if required. To be taken with or without food. Dosage should be individualized based on the patient’s clinical condition and response. Side Effects: Like all medicines, Pioglitazone may cause some side effects, including: Weight gain Fluid retention and edema Headache and muscle pain Risk of heart failure in predisposed patients Increased risk of bone fractures (especially in women) Rare: bladder cancer (long-term use in high doses) Warnings and Precautions: Not recommended in patients with congestive heart failure (CHF) or severe cardiac conditions. Use with caution in patients with liver disease – liver function tests (LFTs) should be monitored. Not indicated for Type 1 Diabetes Mellitus or diabetic ketoacidosis (DKA). Long-term use requires periodic monitoring of weight, edema, and cardiovascular status. Conclusion: PIOSTERIS 30 (Pioglitazone 30 mg) is an effective oral antidiabetic medicine designed to improve insulin sensitivity and provide sustained glycemic control in Type 2 Diabetes Mellitus. When used under medical supervision, it can significantly improve blood sugar management and overall metabolic health.